Kythera Sitting Pretty with $37M for ATX 101 Phase III

Kythera Biopharmaceuticals Inc. closed a Series D financing, landing $37.4 million to launch U.S. Phase III trials for its lead product, ATX 101. The first-in-class injectable is designed to reduce small fat deposits – including those under the chin and jawline, known as submental fat.